INCY - Incyte Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
115.14
-0.50 (-0.43%)
At close: 4:00PM EDT

115.14 0.00 (0.00%)
After hours: 4:35PM EDT

Stock chart is not supported by your current browser
Previous Close115.64
Open116.06
Bid110.00 x 100
Ask117.85 x 400
Day's Range114.78 - 116.94
52 Week Range83.01 - 153.15
Volume1,687,853
Avg. Volume1,508,569
Market Cap24.25B
Beta1.48
PE Ratio (TTM)-145.38
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Incyte Might Win a Cancer-Drug Battle But Lose the War
    Bloomberg2 days ago

    Incyte Might Win a Cancer-Drug Battle But Lose the War

    Even if its suit over alleged IP theft succeeds, the competition is already fierce.

  • Capital Cube3 days ago

    ETFs with exposure to Incyte Corp. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
    Investor's Business Daily3 days ago

    6 Top Biotech Companies In Innovation Earn Recognition In New Awards

    Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?

  • Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease
    Investor's Business Daily3 days ago

    Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease

    Incyte stands out among biotech companies chasing next-generation treatments that work with patients' own immune systems to combat cancer.

  • Forbes9 days ago

    One Of Biotech's Hottest Names Embraces Pharma's Bygone Era

    Incyte has one cancer blockbuster, and it's got Wall Street banking on another. Its secret: embracing an older age of pharma.

  • American City Business Journals12 days ago

    Take a look: Incyte unveils new global headquarters in Wilmington

    While one may expect to have to go to a local park to find a walking trail, community gardens, putting green and a pickleball court side by side, employees of Incyte Corp. will find all those outdoor amenities at the biopharmaceutical company's new global headquarters in Wilmington. Incyte CEO Herve Hoppenot said the expansion was needed to provide more space for the company's growing research and development activities.

  • Capital Cube14 days ago

    ETFs with exposure to Incyte Corp. : October 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Forbes14 days ago

    Cancer-Cure Makers Make Great Takeover Stocks

    This company's impressive technology portfolio make it a great acquisition candidate.

  • 3 Stocks That Turned $7,000 Into $130,200
    Motley Fool20 days ago

    3 Stocks That Turned $7,000 Into $130,200

    There have been some big winners over the past decade, but few have surpassed Priceline Group, Regeneron Pharmaceuticals, and Incyte.

  • Agenus (AGEN) Remains Focused on Drug Development Programs
    Zacks21 days ago

    Agenus (AGEN) Remains Focused on Drug Development Programs

    Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit22 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $8.79 billion.

  • Investopedia23 days ago

    12 Stocks That Will Push the S&P 500 Higher

    Goldman Sachs says sales growth will be the key ingredient driving stocks higher

  • Capital Cube24 days ago

    ETFs with exposure to Incyte Corp. : September 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
    Zacks24 days ago

    Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite

    Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite

  • 3 Monster Biotech Stocks in the Making
    Motley Fool25 days ago

    3 Monster Biotech Stocks in the Making

    They've got successful drugs. They're profitable. All these biotechs need to become huge is a little luck and time.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit28 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • 3 Small-Cap Biotech Stocks to Buy This Fall
    Motley Fool28 days ago

    3 Small-Cap Biotech Stocks to Buy This Fall

    Why small-cap biotechs Celldex Therapeutics, Idera Pharmaceuticals, and NewLink Genetics could be big winners.

  • Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
    Zackslast month

    Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

    Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

  • Reuterslast month

    Lilly/Incyte pill beats placebo in mid-stage eczema trial

    Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis. The finding could be a boost for the drug's prospects, which suffered a setback earlier this year after U.S. regulators turned down an application for its use in rheumatoid arthritis, saying that more data was needed. Baricitinib, in a class of drugs known as Jak inhibitors, is sold in the European Union under the brand name Olumiant for treating rheumatoid arthritis.

  • Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?
    Simply Wall St.last month

    Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?

    Today we’re going to take a look at the well-established Incyte Corporation (NASDAQ:INCY). The company’s stock See our latest analysis for INCY What is INCY worth? INCY appears to beRead More...

  • Reuterslast month

    Lilly/Incyte pill beats placebo in mid-stage eczema trial

    Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis. The finding could be a boost for the drug's prospects, which suffered a setback earlier this year after U.S. regulators turned down an application for its use in rheumatoid arthritis, saying that more data was needed. Baricitinib, in a class of drugs known as Jak inhibitors, is sold in the European Union under the brand name Olumiant for treating rheumatoid arthritis.

  • Capital Cubelast month

    ETFs with exposure to Incyte Corp. : September 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Benzingalast month

    This Analyst Predicts Bullish Growth Outlook For Incyte

    Argus said in a note that it sees bullish growth outlook for Incyte Corporation (NASDAQ: INCY ) given its solid late-stage pipeline and key strategic R&D partnerships with companies such as Merck & Co., ...

  • Incyte Corp. :INCY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
    Capital Cubelast month

    Incyte Corp. :INCY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017

    Categories: Yahoo FinanceGet free summary analysis Incyte Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Incyte Corp. – Celgene Corporation, Amgen Inc., Ligand Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Geron Corporation, Novartis AG Sponsored ADR, Ardelyx, Inc. and AVEO ... Read more (Read more...)

  • Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : September 11, 2017
    Capital Cubelast month

    Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : September 11, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Incyte Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)